You are unique, and your treatment should be too.

To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.

LifeHAck
Introducing Q-Suite™

Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.

Events
Meet us in Barcelona at CIRSE 2019

The Quirem team will attend CIRSE in Barcelona from September 7-11 2019.

previous arrow
next arrow
Slider

SIRT in three steps

Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:

1. SELECT

Select only those patients that are likely to benefit from SIRT. Use QuiremScout®,  a safe dose of holmium microspheres, to evaluate the biodistribution of particles prior to therapy in your patients.

2. TREAT

Treat with QuiremSpheres®, the next-generation microspheres, indicated for treatment of unresectable liver tumors. Click here to learn what value QuiremSpheres® can bring to your clinic.

3. VERIFY

Use our software package Q-SuiteTM to determine SIRT succes right after the procedure, by evaluating the absorbed dose in the lesions and normal liver tissue

News and events

QuiremScout receives CE mark

Terumo Europe today announced that QuiremScout® has received CE mark, making it available as the first and only CE marked product indicated for SIRT work up, for clinical centers throughout Europe. QuiremScout® is designed to

Read More »

What our customers say

logo

Zutphenseweg 55

7418AH Deventer

The Netherlands

Telephone: +31 85 0404170  

E-mail: info@quirem.com